Institutions / CHI Advisors LLC
CHI Advisors LLC
CIK 1791468 · Institution · as of Sep 30, 2023
Portfolio value
$252.09M
Positions
26
As of
Sep 30, 2023
Portfolio trend
Portfolio value
$252.09M-23.5%Positions
26+4.0%Top holdings
Sep 30, 2023View all 26 →
| Company | Value | % of portfolio |
|---|---|---|
| Pliant Therapeutics, Inc.PLRX | $52.27M | 20.7% |
| Repare Therapeutics Inc.RPTX | $35.84M | 14.2% |
| Cullinan Oncology, Inc.CGEM | $30.90M | 12.3% |
| ACELYRIN, Inc.SLRN | $23.01M | 9.1% |
| Orchard Therapeutics PLC | $14.03M | 5.6% |
| Zafgen, Inc.LRMR | $13.49M | 5.4% |
| Keros Therapeutics, Inc.KROS | $13.00M | 5.2% |
| Ikena Oncology, Inc.IKNA | $9.44M | 3.7% |
| Ultragenyx Pharmaceutical Inc.RARE | $7.66M | 3.0% |
| Compass Therapeutics, Inc.CMPX | $5.57M | 2.2% |
| Mineralys Therapeutics, Inc.MLYS | $5.41M | 2.1% |
| Inozyme Pharma, Inc.INZY | $5.33M | 2.1% |
| Syros Pharmaceuticals, Inc.SYRS | $5.12M | 2.0% |
| Blueprint Medicines CorpBPMC | $4.66M | 1.9% |
| Direxion Shs ETF Tr | $4.63M | 1.8% |
| 2seventy bio, Inc.TSVT | $3.93M | 1.6% |
| MoonLake ImmunotherapeuticsMLTX | $3.42M | 1.4% |
| Ovid Therapeutics Inc.OVID | $3.32M | 1.3% |
| Sagimet Biosciences Inc.SGMT | $3.07M | 1.2% |
| Omega Therapeutics, Inc.OMGA | $2.27M | 0.9% |
| Black Diamond Therapeutics, Inc.BDTX | $2.07M | 0.8% |
| Rallybio CorpRLYB | $1.32M | 0.5% |
| Gemini Therapeutics, Inc. /DEIRON | $1.17M | 0.5% |
| Graphite Bio Inc | $572.7K | 0.2% |
| Freeline Therapeutics Hldgs | $372.6K | 0.1% |
Activity
Sep 30, 2023View full history →
InsidersInstitutions
This fund's quarter-over-quarter position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2023 as of | Exit Other (per filing) | 74349U108 | $-100.25M | -934K -100.00% | 0 | high |
| Q1 2021 as of | New Other (per filing) | Cullinan Oncology, Inc. common | $91.77M | +2.2M | 2,202,407 36.40% of portfolio | high |
| Q4 2022 as of | Trim Other (per filing) | 74349U108 | $-74.58M | -678K -42.33% | 923,800 40.31% of portfolio | high |
| Q2 2023 as of | New Other (per filing) | ACELYRIN, Inc. common | $55.67M |